✦ LIBER ✦

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

✍ Scribed by Laginha, Kimberley M.; Moase, Elaine H.; Yu, Ning; Huang, Anthony; Allen, T. M.

Book ID: 126808916
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 166 KB
Volume: 16
Category: Article
ISSN: 1061-186X
DOI: 10.1080/10611860802229978

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Feasibility and Cardiac Safety of Pegyla

Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer

✍ Eleni Andreopoulou; Darci Gaiotti; Eugene Kim; Matthew Volm; Ruth Oratz; Robin F 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 105 KB

Upregulation of mucin4 in ER-positive/HE

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

✍ Albert C. Chen, Ilenia Migliaccio, Mothaffar Rimawi, Sara Lopez-Tarruella, Chad 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 1009 KB

Targeting endothelin A receptor enhances

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

✍ Jeanett Fischgräbe; Martin Götte; Katharina Michels; Ludwig Kiesel; Pia Wülfing 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human breast cancers. It is known to drive tumor growth and progression and represents a prominent target in breast cancer therapy. The endothelin (ET) system, in particular ET-1 and its receptor ET A R, is of major relev

Co-administration of GP96 and Her2/neuDN

Co-administration of GP96 and Her2/neuDNA vaccine in a Her2 breast cancer model

✍ Nafiseh Pakravan; Ladan Langroudi; Monire Hajimoradi; Zuhair Mohammad Hassan 📂 Article 📅 2010 🏛 Springer Netherlands 🌐 English ⚖ 329 KB

Efficacy of HER2-targeted therapy in met

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

✍ Dorte L. Nielsen; Iben Kümler; Jesper A.E. Palshof; Michael Andersson 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 226 KB

A Mathematical Model for the Effects of

A Mathematical Model for the Effects of HER2 Overexpression on Cell Proliferation in Breast Cancer

✍ Amina Eladdadi; David Isaacson 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 550 KB